Compare Inovio Pharmaceuticals Inc (INO) vs Nucor Corporation (NUE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Nucor Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Nucor Corporation trades at $233.54 (market cap $52.55B). The key difference: Nucor Corporation is far larger — about 588.7× Inovio Pharmaceuticals Inc's market cap, and Nucor Corporation pays a 0.97% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NUE | |
|---|---|---|
Market Cap | $89.27M | $52.55B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $266.35 |
52-Week Low | $1.05 | $131.78 |
Enterprise Value | $60.28M | $57.19B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Nucor (NUE) trades at $231.86, down 2.01% today, with a bullish technical signal from moving averages and a consensus analyst price target of $263.11. Recent earnings beat expectations in Q1 2026 with EPS of $3.23 versus $2.82 forecast, though Q4 2025 missed. Revenue trends show recovery from $30.7B in 2024 to $32.5B in 2025, with net income margin improving to 6.82% in 2026 projections. The company maintains a strong balance sheet with a debt-to-asset ratio of 20.23% in 2025 and recently announced a joint venture to support AI power infrastructure.
Outlook remains positive driven by higher steel prices and strategic expansions, but risks include cyclical demand weakness and volatile cash flows. Analyst sentiment is bullish with 62.5% buy ratings, supporting potential upside from current levels, though investors should monitor execution on Q2 2026 earnings expected at $4.45 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →
